TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01114971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl 50 micrograms/ml boluses will be given:~* at the induction time~* at the time before surgical incision, and~* as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR \> 80 bpm)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl 50 micrograms/ml boluses will be given:~* at the induction time~* at the time before surgical incision, and~* as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR \> 80 bpm)
Study: NCT02077218

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Undergo cardiac CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cytology specimen collection procedure
Description: Undergo collection of blood samples

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study: NCT02329938

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lichtenstein tension free reair
Description: a mesh is apllied on the posterior wall of the inguinal canal and sutured to the inguinal ligament below, to the internal oblique muscle above , and to rectus sheath medially.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Desarda's repair
Description: the repair is done using a flap of the external oblique aponeurosis sutured to the inguinal ligament below and to the aponeurotic part of the internal oblique muscle above.
Study: NCT00764686

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise and Education
Description: One hydrotherapy class, one land-exercise class and one education session daily, for five days. Each exercise class and education session is one hour in duration.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise and Education
Description: Two hydrotherapy classes, one land-exercise class and one education session daily, for five days. Each exercise class and education are one hour in duration.
Study: NCT02332837

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention A: Questionnaire accuracy
Description: Participants will be tested by questionnaire to measure how well consent is understood

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention A: Questionnaire accuracy
Description: Participants will be tested by questionnaire to measure how well consent is understood

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention A: Questionnaire accuracy
Description: Participants will be tested by questionnaire to measure how well consent is understood

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention B: Questionnaire speed of completion
Description: Time to complete questionnaire from time of presentation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention B: Questionnaire speed of completion
Description: Time to complete questionnaire from time of presentation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention B: Questionnaire speed of completion
Description: Time to complete questionnaire from time of presentation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention C: Questionnaire Completion rate
Description: Number of participants who complete the questionnaire

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention C: Questionnaire Completion rate
Description: Number of participants who complete the questionnaire

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention C: Questionnaire Completion rate
Description: Number of participants who complete the questionnaire
Study: NCT04480710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRV431 75mg
Description: 1 x 75mg softgel capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (1 softgel)
Description: 1 x placebo softgel capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRV431 225mg
Description: 3 x 75mg softgel capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (3 softgels)
Description: 3 x placebo softgel capsule
Study: NCT03079635

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Beverage provided and a four hour postprandial assessment of energy metabolism using a metabolic cart and appetite using a visual analog scale follows.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Beverage provided and a four hour postprandial assessment of energy metabolism using a metabolic cart and appetite using a visual analog scale follows.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3 fatty acids
Description: Beverage provided and a four hour postprandial assessment of energy metabolism using a metabolic cart and appetite using a visual analog scale follows.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3 fatty acids
Description: Beverage provided and a four hour postprandial assessment of energy metabolism using a metabolic cart and appetite using a visual analog scale follows.
Study: NCT04349943

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nutrition therapy
Description: With enteral nutrition as the preferred solution, the gradual transition from slow to fast, from lean to dense, from essential to whole protein type is conducted.
Study: NCT03443271

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP Block with Bupivicaine
Description: Ultrasound guided TAP block will be performed and patient will be administered 20 ml of 0.25 % Bupivicaine on each side.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: TAP Block with Placebo drug
Description: Ultrasound guided TAP block will be performed and patient will be administered 20 ml of 0.9% Saline on each side.
Study: NCT01114971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Labetalol
Description: Labetalol 5 mg/ml boluses will be given:~* at the induction time~* at the time before surgical incision, and~* as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR \> 80 bpm)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Labetalol
Description: Labetalol 5 mg/ml boluses will be given:~* at the induction time~* at the time before surgical incision, and~* as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR \> 80 bpm)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmolol
Description: Esmolol 10 mg/ml boluses will be given:~* at the induction time~* at the time before surgical incision, and~* as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR \> 80 bpm)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: Esmolol 10 mg/ml boluses will be given:~* at the induction time~* at the time before surgical incision, and~* as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR \> 80 bpm)
Study: NCT01127607

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lisdexamfetamine
Description: 3 week with-in subject lead in phase to find optimal dose ranging from 30 mg to 70mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lisdexamfetamine
Description: 3 week with-in subject lead in phase to find optimal dose ranging from 30 mg to 70mg
Study: NCT00633568

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concomitant Radiochemotherapy - Radiotherapy 66 Gy, Cisplatin, and Docetaxel
Description: Concurrent chemoradiotherapy: Radiotherapy 66 Gy in 2 Gy/fraction, 5 fractions/wk (6.5 weeks)with Cisplatin 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy)and Docetaxel 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy) Chemotherapy : Cisplatin 60 mg/m² and Docetaxel 75 mg/m² on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concomitant Chemoradiotherapy - Radiotherapy 66 Gy, Cisplatin, and Docetaxel
Description: Concurrent chemoradiotherapy: Radiotherapy 66 Gy in 2 Gy/fraction, 5 fractions/wk (6.5 weeks)with Cisplatin 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy)and Docetaxel 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy) Chemotherapy : Cisplatin 60 mg/m² and Docetaxel 75 mg/m² on day 1
Study: NCT05451706

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Mental help-seeking self-persuasion
Description: Employing a longitudinal design, this study used a self-persuasion framework in a 4-arm intervention to increase college students' help-seeking intentions during the COVID-19 pandemic.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mental help-seeking self-persuasion
Description: Employing a longitudinal design, this study used a self-persuasion framework in a 4-arm intervention to increase college students' help-seeking intentions during the COVID-19 pandemic.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Mental help-seeking self-persuasion
Description: Employing a longitudinal design, this study used a self-persuasion framework in a 4-arm intervention to increase college students' help-seeking intentions during the COVID-19 pandemic.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental help-seeking self-persuasion
Description: Employing a longitudinal design, this study used a self-persuasion framework in a 4-arm intervention to increase college students' help-seeking intentions during the COVID-19 pandemic.
Study: NCT03119181

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Tymbion Lidocaine/epinephrine solution
Description: The external ear canal will be filled with Tymbion drug solution

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Device: Iontophoresis System (IPS) with Drug: Tymbion lidocaine/epinephrine solution
Description: The external ear canal will be filled with Tymbion drug solution. The Iontophoresis System (IPS) will be used to deliver current to the Tymbion solution to facilitate drug penetration into the tympanic membrane (TM) tissue to anesthetize (numb) the TM
Study: NCT02399540

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Bihemispheric 1mA Sham protocol: sham - pause - sham

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Paired tDCS
Description: Bihemispheric 1mA Sham protocol: sham - pause - sham Conventional Paired tDCS protocol: 20 minutes tDCS - pause - sham

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Unpaired tDCS
Description: Bihemispheric 1mA Sham protocol: sham - pause - sham Conventional Unpaired tDCS protocol: 20 minutes tDCS - pause - sham

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Late LTP-like Plasticity tDCS
Description: Bihemispheric 1mA Sham protocol: sham - pause - sham Late LTP-like Plasticity tDCS protocol: 10 minutes tDCS - 25 minutes pause - 10 minutes tDCS
Study: NCT01208961

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epanova (4 g) and Lovaza (4 g)
Description: Single dose of Epanova (omefas), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Lovaza (omega-3-acid ethyl esters), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Epanova (omefas), 4x1g capsules, taken with high-fat meals, 7 day washout followed by single dose of Lovaza (omega-3-acid ethyl esters, 4x1g capsules, taken with high-fat meals

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lovaza (4 g) and Epanova (4 g)
Description: Single dose of Lovaza (omega-3-acid ethyl esters), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Epanova (omefas), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Lovaza (omega-3-acid ethyl esters,4x1g capsules, taken with high-fat meals, 7 day washout followed by single dose ofEpanova (omefas),4x1g capsules, taken with high-fat meals
Study: NCT03321123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB-CART19.1
Description: Miltenyi Biotec has established a semi-automated manufacturing process that can be made available to academic settings for systematic exploration of CAR strategies in advanced clinical studies. Closed-system operation, improved robustness, simplified work flows, and reduced labor intensity, while maintaining strict adherence to regulatory guidelines, allows for decentralized manufacturing. In this study, we will explore autologous 2nd generation CD19 CAR T cell products in patients with relapsed and refractory disease incurable with standard therapies.
Study: NCT02285790

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reflectance confocal microscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Punch biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical excision
Description: Excision of the suspected basal cell carcinoma lesion under local anesthetics

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical excision
Description: Excision of the suspected basal cell carcinoma lesion under local anesthetics
Study: NCT01366209

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pirfenidone
Description: Pirfenidone, total daily dose of 2403 mg/ day, given as 3 divided doses 3 times per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo equivalent given as 3 divided doses 3 times per day.
Study: NCT01655706

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: escitalopram
Description: Patients will be given escitalopram for the first 8 weeks of the trial. At week 8, patients who are assessed as 'responders' will continue on escitalopram until study endpoint.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: escitalopram
Description: Patients will be given escitalopram for the first 8 weeks of the trial. At week 8, patients who are assessed as 'responders' will continue on escitalopram until study endpoint.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aripiprazole
Description: At Week 8, patients assessed as 'non-responders' will be given aripiprazole as an add-on treatment to escitalopram.
Study: NCT02475343

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Schiotz tonometer
Description: The corneal biomechanical properties will be measured using a Schiotz tonometer with routine manipulation protocol.This measurement will be used in normal people, keratoconic patients, patients received keratoplasty.
Study: NCT02225847

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gardening
Description: The intervention consists of twice weekly group sessions of gardening activities of 60 minutes in duration that will take place in a greenhouse. A total of 12 gardening sessions administered over a period of six weeks will include planting seeds, bulbs and tubers, transplanting seedlings, vegetative propagation and sight, smell, taste and touch sensory based activities.
Study: NCT02475343

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UVA/riboflavin
Description: The UVA/riboflavin corneal crosslinking will be applied using a UV-X lamp (Peschke Meditrade GmbH, Switzerland) with routine manipulation protocol (3mW/cm2, 365nm, 30 minutes).This treatment will be used in keratoconic patients.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UVA/riboflavin
Description: The UVA/riboflavin corneal crosslinking will be applied using a UV-X lamp (Peschke Meditrade GmbH, Switzerland) with routine manipulation protocol (3mW/cm2, 365nm, 30 minutes).This treatment will be used in keratoconic patients.
Study: NCT02225847

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Functional Magnetic Resonance Imaging (fMRI)
Description: Functional magnetic resonance imaging will be employed to assess whether engaging in gardening activities in a greenhouse does or does not alter the spatial patterns of brain network activation relative to changes that occur between the groups.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional Magnetic Resonance Imaging (fMRI)
Description: Functional magnetic resonance imaging will be employed to assess whether engaging in gardening activities in a greenhouse does or does not alter the spatial patterns of brain network activation relative to changes that occur between the groups.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: psychometric assessments
Description: The following assessments will be used: The SF-36 Health Survey assessment instrument (Ware and Sherbourne 1992; Hays et al 1993), the Beck Depression Inventory 2nd edition (BDI-II) (Beck et al 1988), The State Trait Anxiety Inventory (STAI) instrument (Form Y) (Spielberger et al 1983), the Profile of Mood States 2nd edition short form for adults instrument (POMS2-AS), and the Perceived Stress Scale (PSS) (Cohen et al 1983) for changes that occur in between the groups.
Study: NCT05311540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc Sulfate
Study: NCT02225847

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychometric assessments
Description: The following assessments will be used: The SF-36 Health Survey assessment instrument (Ware and Sherbourne 1992; Hays et al 1993), the Beck Depression Inventory 2nd edition (BDI-II) (Beck et al 1988), The State Trait Anxiety Inventory (STAI) instrument (Form Y) (Spielberger et al 1983), the Profile of Mood States 2nd edition short form for adults instrument (POMS2-AS), and the Perceived Stress Scale (PSS) (Cohen et al 1983) for changes that occur in between the groups.
Study: NCT01753791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 80 mg PF-06473871
Description: 80 mg of PF-06473871 or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 160 mg PF-06473871
Description: 160 mg of PF-06473871 or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 320 mg PF-06473871
Description: 320 mg of PF-06473871 or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 480 mg PF-06473871
Description: 480 mg of PF-06473871 or placebo
Study: NCT05510804

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ALISA
Description: assisted self-help smartphone application featuring virtual reality within a structured CBT programme / low-frequency scheduled therapist assistance

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: ALISA
Description: assisted self-help smartphone application featuring virtual reality within a structured CBT programme / low-frequency scheduled therapist assistance
Study: NCT01492049

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CRCS patient decision aid (PtDA) video
Description: Participant views PtDA program video in same room as research assistant who offers instruction as needed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Up to 3 questionnaires (baseline demographics, post-intervention evaluation, and follow up) taking from 5 to 25 minutes to complete each.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Up to 3 questionnaires (baseline demographics, post-intervention evaluation, and follow up) taking from 5 to 25 minutes to complete each.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Essential Hypertension video
Description: Participant views Essential Hypertension video in same room as research assistant who offers instruction as needed.
Study: NCT03961451

Intervention type: DEVICE
Intervention: Podometer
Description: Patients will be equipped with pedometers for 8 weeks, all day and must complete the number of steps each day. They will have to complete online evaluation questionnaires regularly. The main objective is to correlate the level of physical activity with the level of fatigue, quality of life and well-being weekly during an anticancer treatment.

Intervention type: DEVICE
Intervention: Podometer
Description: Patients will be equipped with pedometers for 8 weeks, all day and must complete the number of steps each day. They will have to complete online evaluation questionnaires regularly. The main objective is to correlate the level of physical activity with the level of fatigue, quality of life and well-being weekly during an anticancer treatment.
Study: NCT03301870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATx201 Gel 2%
Description: 2% active gel
Study: NCT02460614

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rhinopharyngeal clearance
Description: At the end of the expiratory time, the child's mouth was closed by the hand of the researcher (raising the lower jaw), leading the child to perform a nasal aspiration maneuver.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aspiration
Description: A sterile aspiration catheter was connected to an extension and carefully introduced into the nasal cavity of the patient.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% saline
Description: 0.9% saline consists of physiological solution and was instilled in both experimental groups.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0.9% saline
Description: 0.9% saline consists of physiological solution and was instilled in both experimental groups.
Study: NCT04666389

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: To compare the preventive role of low- and high-dose statin regimens in the prevention on contrast-induced acute kidney injury in statin-naive patients with cardiovascular diseases undergoing computer tomography with intravenous contrast media administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: To compare the preventive role of low- and high-dose statin regimens in the prevention on contrast-induced acute kidney injury in statin-naive patients with cardiovascular diseases undergoing computer tomography with intravenous contrast media administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: To compare the preventive role of low- and high-dose statin regimens in the prevention on contrast-induced acute kidney injury in statin-naive patients with cardiovascular diseases undergoing computer tomography with intravenous contrast media administration